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Little is known about how adolescents experience clinical trials. We 
assessed the experiences of South African adolescent participants 
in a clinical trial, employing semi-structured interviews to gather 
qualitative data on the experiences and effects of trial participation. 
Despite misunderstanding certain concepts regarding assent and 
trial processes subsequent to enrolment, participants reported 
positive experiences overall. Subjects’ motivations for participation 
included: an ability to help others; receipt of healthcare; and free 
blood screening. Participants expressed fears associated with trial 
procedures, such as phlebotomy; however, these apprehensions 
diminished as the trial progressed. We found that conducting 
qualitative research within a trial site is feasible, and can provide 
insight into the uptake and acceptability of interventions. 
S Afr Med J 2011;101:884-886.
Healthcare workers often practise dose extrapolation when 
prescribing medicines for children (≤ 18 years) owing to lack of data 
for this group.1 Incentives and legislation aimed at addressing this 
gap2 may increase the number of child-focused trials. However, there 
is little research on how this age group experiences clinical trials.3
Methods
We aimed to assess the experience of adolescent trial participants and 
evaluate the feasibility of conducting qualitative research within a 
clinical trial. The trial site was in the Breede Valley, Western Cape, where 
tuberculosis (TB) is endemic. Respondents were participants in a phase 
1, randomised, placebo-controlled trial of a novel TB vaccine candidate.
We used a qualitative approach and conducted semi-structured 
interviews. Purposeful sampling was intended to ensure that 
expressed views reflected the diversity of the study population. 
Interviews were conducted in English with available interpretation 
in isiXhosa and Afrikaans. Interviews were subsequently transcribed, 
and translated into English by transcribers who were unaware of the 
research aims and participants’ identities. We used manual thematic 
content analysis to identify emerging themes. Ethics committee 
approval of the study was obtained from the Medical Research 
Council and the University of Cape Town. 
Results
After trial closure, 17 interviews had been conducted. Participants 
ranged from 13 to 18 years of age (median age 16). All participants 
spoke English at school. Home languages included Afrikaans 
(9 participants), isiXhosa (4), English (2) and a combination of 
languages (English/Afrikaans (1); English/isiXhosa (1)). 
Most participants (9) reflected positively on trial participation; 3 
described positive experiences despite instances of fear, e.g. ‘It was 
very exciting … when we’re going along with the other children, 
we used to be scared … but I really enjoyed it.’ Two respondents 
conveyed a positive experience while reflecting on pain: ‘It was nice 
… but sometimes it was a little bit sore with the needles … but … you 
start to get used to it.’ 
Participants varied in their knowledge of TB prior to the trial 
(Table I), and had learned of the trial from numerous sources (Table 
II). Fourteen participants discussed which person had assisted them 
with their decision to assent: 10 stated that a parent had helped them 
with their decision, 9 of whom said that this parent was their mother, 
and 2 stated that their mothers had enrolled them in the study.
Motivations to participate were found to be multifactorial (Table 
III). The benefits of transport to the trial site, paired with altruistic 
urges to donate blood, were strong factors. Some participants 
hesitated to admit that ‘money’ motivated participation, but others 
were forthcoming: ‘The money . . . helped us a lot, we even paid our 
burial society.’ Health-seeking reasons were the most cited (8): ‘It was 
an opportunity for me to know what my status is.’ Altruistic urges 
(7) were important motivators: ‘Mostly I didn’t actually come for the 
money, I just came to get my blood statuses and to donate blood, 
mostly it was just donating my blood.’
Participants were prompted to reflect on the day before their 
first visit, and their overall emotions regarding trial participation; 7 
described their excitement and usefulness owing to their involvement: 
‘I was excited and a little bit shy also … It’s not like every day they put a 
needle in your arm.’  ‘I felt useful for a change. ’ Five subjects reflected 
positively on the experience, stating that they felt comfortable; 3 
remembered feeling scared initially, but, with increasing exposure 
to trial procedures, fears decreased. Although only 3 participants 
described feeling frightened, several revealed fears when discussing 
other aspects of participation: fears related to injections (6), the 
drawing of blood (3), blood test results (3) and anticipation (1).
Trial visits were an opportunity for subjects to connect with fellow 
community members, and to meet new people. All respondents made 
new connections at the trial site: 7 maintained contact while others 
(10) lost contact because the site visits ended. 
Fifteen participants reported positive experiences with staff 
members, while highlighting the ability of the staff to amuse and 
explain procedures: ‘They were easy to talk to, and can make you 
laugh at times. You get used to them. And then later on, they were 
like your friends.’
Participants differed in their perceptions of the purpose of the trial. 
Eleven thought that they understood the research, but only a few 
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could explain the aim of the trial when asked to do so; 3 understood 
that the trial intended to test the efficacy of a TB vaccine (‘It’s to study 
if the vaccine was protecting you against TB’); 3 believed that the trial 
aimed to find an antidote to TB but did not expressly state that it was 
a vaccine trial; and 4 misunderstood the trial as blood screening for 
TB (‘It was so that you could know if you were sick or – if you have 
TB’). Two participants understood the research as blood donation: 
‘I just know that, because they need more blood for other people.’ 
Four participants stated that they did not know what the research 
aims were. Confusion between the drawing of blood (for screening) 
and blood donation was evident. Vaccine, injection and blood-
drawing terminology were often used interchangeably. A minority (3) 
understood TB to be a sexually transmitted disease.
Eleven participants were able to recall the consent/assent process, 5 
could not, and 1 reported that he/she was not present but that his/her 
mother was (in order for the formal consent process to be validated, 
the participant had to be present during a consenting session). 
Perceived benefits that emerged when discussing the effect of 
the trial on participants’ lives included increased awareness of TB 
(2), increased awareness of healthcare issues and places to access 
healthcare (2), overcoming the fear of needles/injections (2), access 
to a doctor (1), absence from school (1) and free blood screening 
(1). Participants stated that ‘This place was good for me because I 
wouldn’t have known if I had been ill’ , ‘I didn’t even know what TB 
was before I started … ’ , and ‘I’m very afraid of needles, so I got over 
the fear of the sting.’
When asked for suggestions on how to improve their trial 
experience, 11 subjects stated that they would not change anything; 
only 1 reflected on the trial process: ‘New technology so that stuff can 
go faster when they are taking your blood.’ 
All but 2 respondents answered that there were no negative aspects 
to their participation in the trial. 
Discussion 
We believe that this is the first South African study evaluating the 
experiences of adolescents in a TB vaccine trial. Overall, subjects’ 
experiences were positive. Motivations to participate included: an 
ability to help others; receipt of healthcare; and free blood screening. 
Consistency of the employ of staff members whom participants knew 
from the community, and the provision of information by the former 
while maintaining a light mood were integral to participants’ positive 
trial experiences. Qualitative research provided information-rich 
data that highlighted themes most salient to adolescent participants4 
and the utility of such findings for informing trial research. 
As with previous research,5 motivation to participate was driven 
primarily by altruism and health-seeking behaviour. Most subjects 
relied on their mothers’ approval. Some suggested that their mothers 
had enrolled them in the trial, raising issues of whether assent 
can be withheld when parents have consented, especially where 
participation results in income for families.6 Context-based research 
is needed to understand the pressures that adolescents face in the 
decision-making process.
Participants recalled their fear of needles, blood collection and test 
results, which decreased with ongoing exposure. Trial participation, 
with pre-test counselling, could therefore reduce subjects’ fears and 
other concerns. 
The misunderstanding of the trial aims was not specific to the 
participants in this study. Misconceptions that trial participation 
protects participants from the researched disease need to be 
dispelled.7 Some participants were unaware that trial participation 
had prophylactic potential, instead believing that the purpose of the 
trial was for blood donation or screening. 
Obtaining informed consent does not necessarily equate to 
informed participants. Limited recall of the informed consent process 
may indicate that less emphasis should be placed on a single informed 
Table I. TB knowledge questions
Question Yes No No answer Did not know Other
Did you know what TB was before you participated? 12 5 0 0 0
Do you know how TB affects your body or what the symptoms are? 11 4 0 0 2
Do you know anyone who has TB? 4 12 1 0 0
Do you think TB is a problem in the community in which you live? 6 8 0 2 1
Do you think the way you understand or what you know about TB has changed since taking part? 9 7 1 0 0
Table II. Recruitment
Sources from which participants learned of the trail N
Mother* 5
Father* 1
Other family members 2
Peers or friends 3
School 2
Direct contact with research staff (not family members) 2
Community members 1
Multiple parties listed above 1
*Three participants were children of trial staff and were recruited through their parents (2 
mothers, 1 father)
Table III. Motivations for subject participation
Motivation N
Interesting 1
Blood screening (health-seeking) 4
Blood donation (helping others) 1
‘Money’ 2
‘To fight against TB’ 1
Interesting, blood donation (helping others) and absence  
from school 1
Blood donation (helping others) and blood screening 2
Blood donation (helping others) and ‘money’ 2
Blood screening (health-seeking) and ‘money’ 2
Blood donation (helping others) and absence from school 1
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consent session. Continuous consent,8 or repetition paired with 
discussion of trial details, may dispel confusion. 
Strengths and limitations 
The study strengths lie in trial participants being allowed the 
opportunity to voice their opinions. The time lapse of nearly a year 
between initial trial consent/assent and the subsequent interviews 
possibly limited recall. Interviews were conducted during a school 
holiday break which might have resulted in more positive responses, 
whereas those with negative experiences might have been less likely 
to attend interviews. Conducting interviews at the trial site might 
have introduced response bias. The use of interpreters during 
interviews might have led to loss of response nuances. 
Further research is needed to understand adolescent consent/
assent experiences and their comprehension of the processes involved. 
This applies particularly to participant counselling in the context of 
limited funds. Ethnographic research should focus on understanding 
participation in a wider context.
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